United States Digital Therapeutics Market to Grow with a CAGR of 22.77% through 2030

Adoption of telehealth & remote patient monitoring systems and increasing incorporation of digital health technology in mental health expected to drive the United States Digital Therapeutics Market growth in the forecast period, 2026-2030. 

According to TechSci Research report, “United States Digital Therapeutics Market –Industry Size, Share, Trends, Competition Forecast & Opportunities, 2030”, the United States Digital Therapeutics Market stood at USD 1.58 Billion in 2024 and is anticipated to project steady growth in the forecast period with a CAGR of 22.77% through 2030. The United States Digital Therapeutics Market is experiencing significant growth, driven by several key factors. The heightened prevalence of chronic diseases, such as diabetes and cardiovascular conditions, has created a pressing need for innovative solutions to manage and treat these conditions effectively. There is a growing focus on preventive healthcare, with individuals and healthcare providers recognizing the importance of early intervention and proactive measures to maintain health and well-being. Moreover, the upsurge in smartphone and internet usage has provided a fertile ground for digital therapeutics to thrive. These technologies leverage the power of mobile devices and connectivity to deliver personalized and accessible healthcare solutions to individuals anytime, anywhere. This convenience and accessibility have revolutionized the way healthcare is delivered, empowering individuals to take control of their health and engage in self-care.

Browse over XX market data Figures spread through XX Pages and an in-depth TOC on "United States Digital Therapeutics Market.”

United States Digital Therapeutics Market is segmented into product, sales channel, application, regional distribution, and company.

Based on Sales Channel, In the United States Digital Therapeutics (DTx) market, the Business-to-Business (B2B) sales channel holds the position of the fastest-growing segment. This growth is largely driven by the increasing adoption of digital health solutions by large-scale stakeholders such as healthcare providers, insurance companies, employers, and pharmaceutical firms. These institutions are recognizing the value of DTx in enhancing patient outcomes, managing chronic conditions, and reducing healthcare costs. Unlike direct-to-consumer (DTC) models, B2B partnerships allow for broader population-level deployment and more measurable returns on investment. For example, employers are increasingly incorporating digital therapeutics into wellness and employee assistance programs, while insurers are reimbursing DTx interventions for conditions such as diabetes, depression, and substance use disorders. The integration of DTx into electronic health records (EHRs) and existing care pathways further supports its scalability in institutional settings.

Based on Region, In the United States digital therapeutics market, the Northeast region is emerging as the fastest-growing hub. This accelerated growth is driven by several factors, including the region’s high concentration of academic medical centers, forward-thinking health systems, and influential policy environments. States like Massachusetts, New York, and Pennsylvania are home to renowned institutions that frequently pilot and adopt innovative digital treatment modalities—especially for chronic illnesses, mental health, and substance use disorders. These early adopters lend credibility to digital therapies, encouraging wider acceptance across clinical settings. Moreover, the Northeast hosts a dense cluster of biotechnology and health-tech startups, particularly around Boston and New York City. This robust ecosystem facilitates partnerships between digital therapeutics companies, academic researchers, clinicians, and payers. These collaborations often result in evidence-based, FDA-cleared DTx tools being integrated into regional care pathways, fueling demand and adoption.

Major companies operating in the United States Digital Therapeutics Market are:

• Noom Inc.
• Omada Health Inc.
• WellDoc, Inc.
• Pear Therapeutics Inc.
• Proteus Digital Health Inc.
• Resmed, Inc. (Propeller Health)
• Akili Interactive Labs, Better Therapeutics
• 2Morrow Inc.
• Ginger, Fitbit Inc. (Twin Health Inc.)
• Livongo Health, Inc.

Download Free Sample Report

Customers can also request 10% free customization on this report.

“The future of the United States Digital Therapeutics Market is poised for significant growth. The increasing prevalence of chronic diseases, such as diabetes and cardiovascular conditions, creates a pressing need for innovative solutions that can effectively manage and treat these conditions. Additionally, the surge in preventive healthcare, with individuals becoming more proactive in managing their health and well-being, further drives the demand for digital therapeutics. Technological advancements in artificial intelligence, machine learning, and big data analytics play a crucial role in the growth of the digital therapeutics market. These technologies enable the development of sophisticated algorithms and predictive models that can analyze vast amounts of patient data, leading to more accurate diagnoses and tailored treatment plans. Furthermore, strategic collaborations between digital therapeutic startups and pharmaceutical companies are anticipated to unlock new avenues for market expansion. By combining expertise and resources, these partnerships can accelerate the development and commercialization of innovative digital therapeutic solutions. The future of the United States Digital Therapeutics Market is promising, with immense potential to revolutionize healthcare delivery and improve patient outcomes. As technology continues to advance and regulatory frameworks evolve, digital therapeutics are expected to play an increasingly vital role in the management of chronic diseases and the overall transformation of healthcare.,” said Mr. Karan Chechi, Research Director of TechSci Research, a research-based management consulting firm.

“United States Digital Therapeutics Market By Product (Software, Device), By Sales Channel (B2B, B2C), By Application (Preventive Applications, Treatment Applications), By Region, Competition, Forecast and& Opportunities, 2020-2030F”, has evaluated the future growth potential of United States Digital Therapeutics Market and provides statistics & information on market size, structure and future market growth. The report intends to provide cutting-edge market intelligence and help decision-makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges, and opportunities in United States Digital Therapeutics Market.

Contact

TechSci Research LLC

420 Lexington Avenue, Suite 300,

New York, United States- 10170

Tel: +1-332-258-6602

Email: sales@techsciresearch.com

Website: www.techsciresearch.com